Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Recommendation of “Moderate Buy” by Analysts

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has been given a consensus rating of “Moderate Buy” by the fourteen analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and thirteen have issued a buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $45.80.

Several research analysts recently issued reports on the stock. Mizuho increased their price target on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Avalo Therapeutics in a research note on Friday, July 24th. Citizens Jmp lowered their target price on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a report on Thursday, May 14th. Citigroup restated an “outperform” rating on shares of Avalo Therapeutics in a research note on Wednesday, May 6th. Finally, Bank of America started coverage on Avalo Therapeutics in a research report on Friday, June 12th. They set a “buy” rating and a $35.00 price objective for the company.

Insider Activity at Avalo Therapeutics

In other news, insider Mittie Doyle sold 1,450 shares of the stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total value of $26,100.00. Following the sale, the insider directly owned 51,776 shares of the company’s stock, valued at approximately $931,968. This represents a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.46% of the company’s stock.

Institutional Trading of Avalo Therapeutics

Institutional investors have recently bought and sold shares of the company. Caligan Partners LP bought a new position in shares of Avalo Therapeutics in the third quarter worth approximately $10,592,000. Balyasny Asset Management L.P. bought a new position in Avalo Therapeutics in the 3rd quarter valued at approximately $10,390,000. Vanguard Group Inc. boosted its stake in Avalo Therapeutics by 314.9% during the 3rd quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock valued at $8,803,000 after purchasing an additional 525,696 shares during the last quarter. Millennium Management LLC boosted its stake in Avalo Therapeutics by 380.2% during the 4th quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock valued at $11,985,000 after purchasing an additional 522,548 shares during the last quarter. Finally, Seven Fleet Capital Management LP increased its holdings in shares of Avalo Therapeutics by 806.0% in the 1st quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock worth $8,568,000 after purchasing an additional 510,540 shares in the last quarter. 87.06% of the stock is owned by hedge funds and other institutional investors.

Avalo Therapeutics Trading Down 0.7%

AVTX opened at $18.70 on Friday. The stock has a fifty day simple moving average of $17.22 and a two-hundred day simple moving average of $16.27. The company has a market cap of $989.23 million, a price-to-earnings ratio of -3.42 and a beta of 0.80. Avalo Therapeutics has a 12-month low of $8.01 and a 12-month high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last announced its earnings results on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). On average, analysts predict that Avalo Therapeutics will post -2.58 EPS for the current year.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.